Loading
journalsJournal
Nature Biotechnology
Nature Biotechnology is the leading biotechnology journal, covering new sequencing and single-cell methods, CAR-T and gene-editing engineering, ADC and protein design, plus biotech industry analysis.
Also called: Nat Biotechnol
Overview
Nature Biotechnology (Nat Biotechnol) is the leading biotechnology journal, founded in 1983, appearing monthly and published by Springer Nature on a hybrid access model. It publishes methods and tools such as single-cell and spatial omics, base and prime editing and protein design, together with engineered therapeutics including next-generation CAR-T cells, bispecifics and ADCs, and its news section tracks the biotech industry and regulation. Its readers are technologists, cell and gene therapy engineers and industry watchers. Within OnCo it is linked from the Andreas Trumpp biography, and a reader would use it for new sequencing and single-cell methods and for the engineering behind cell therapies and antibody constructs.
Publisher
Springer Nature
Scope
biotechnology
Website
Access model
hybrid
Founded
1983
ISSN
1087-0156
observational2024339 citations
Predicting transcriptional outcomes of novel multigene perturbations with GEARS
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observational2021310 citations
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
basic20201,274 citations
Human chimeric antigen receptor macrophages for cancer immunotherapy
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
review20121,148 citations
Russell, Peng and Bell 2012: the field states its own problems
Read against what happened next, this review is a fair scorecard. The immune timing problem, the delivery threshold and the manufacturing yield are still the reasons most programmes fail, and the proliferation of platforms the authors warned about is still the reason the field has many products and few randomised wins.
basic2003896 citations
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Andreas Trumpp
Head of Stem Cells and Cancer, DKFZ; Managing Director, HI-STEM
Cancer stem cellsMetastasisCirculating tumour cells
Andreas Trumpp is a stem cell biologist studying how dormant cancer cells seed metastases and resist therapy.
John C. Bell
Senior Scientist, Cancer Research Program, Ottawa Hospital Research Institute; University of Ottawa
Oncolytic virotherapyVesicular stomatitis virusVaccinia virus
John Bell's laboratory showed that cancer cells which have broken their interferon alarm cannot defend themselves against a virus, the mechanism the whole field is built on.
Robert S. Langer
David H. Koch (1962) Institute Professor
Drug deliveryBiomaterialsNanomedicine
Biomedical engineer whose Koch Institute lab pioneered controlled drug delivery and nanomedicine, including approaches to cancer therapy.
Silvana Konermann
Executive Director and Core Investigator, Arc Institute
Functional genomicsCRISPR technologiesNeurodegeneration
Neuroscientist and co-founder who runs the Arc Institute, an independent research institute in the San Francisco Bay Area built to tackle complex diseases.
Stephen J. Russell
Molecular medicine researcher, Mayo Clinic, Rochester; also affiliated with Vyriad, Rochester
Oncolytic virotherapyEngineered measles virusMyeloma
Stephen Russell built the engineered measles viruses used against cancer and reported the case in which one intravenous dose put a patient's myeloma into complete remission.
observationalNature Biotechnology 2024339 citations
Predicting transcriptional outcomes of novel multigene perturbations with GEARS
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalNature Biotechnology 2021310 citations
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
basicNature Biotechnology 20201,274 citations
Human chimeric antigen receptor macrophages for cancer immunotherapy
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
reviewNature Biotechnology 20121,148 citations
Russell, Peng and Bell 2012: the field states its own problems
Read against what happened next, this review is a fair scorecard. The immune timing problem, the delivery threshold and the manufacturing yield are still the reasons most programmes fail, and the proliferation of platforms the authors warned about is still the reason the field has many products and few randomised wins.
basicNature Biotechnology 2003896 citations
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Similar pages
technologies
terms
people
key papers
Development of potent monoclonal antibody auristatin conjugates for cancer therapyEnhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNAHuman chimeric antigen receptor macrophages for cancer immunotherapyPredicting transcriptional outcomes of novel multigene perturbations with GEARSRussell, Peng and Bell 2012: the field states its own problems